286 related articles for article (PubMed ID: 10764044)
1. Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas.
Sung T; Miller DC; Hayes RL; Alonso M; Yee H; Newcomb EW
Brain Pathol; 2000 Apr; 10(2):249-59. PubMed ID: 10764044
[TBL] [Abstract][Full Text] [Related]
2. Genetic alterations in pediatric high-grade astrocytomas.
Cheng Y; Ng HK; Zhang SF; Ding M; Pang JC; Zheng J; Poon WS
Hum Pathol; 1999 Nov; 30(11):1284-90. PubMed ID: 10571506
[TBL] [Abstract][Full Text] [Related]
3. p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma.
Fulci G; Labuhn M; Maier D; Lachat Y; Hausmann O; Hegi ME; Janzer RC; Merlo A; Van Meir EG
Oncogene; 2000 Aug; 19(33):3816-22. PubMed ID: 10949938
[TBL] [Abstract][Full Text] [Related]
4. Genetic profile of gliosarcomas.
Reis RM; Könü-Lebleblicioglu D; Lopes JM; Kleihues P; Ohgaki H
Am J Pathol; 2000 Feb; 156(2):425-32. PubMed ID: 10666371
[TBL] [Abstract][Full Text] [Related]
5. Molecular genetics of radiographically defined de novo glioblastoma multiforme.
Tortosa A; Ino Y; Odell N; Swilley S; Sasaki H; Louis DN; Henson JW
Neuropathol Appl Neurobiol; 2000 Dec; 26(6):544-52. PubMed ID: 11123721
[TBL] [Abstract][Full Text] [Related]
6. Molecular pathogenesis of malignant gliomas.
Rasheed BK; Wiltshire RN; Bigner SH; Bigner DD
Curr Opin Oncol; 1999 May; 11(3):162-7. PubMed ID: 10328589
[TBL] [Abstract][Full Text] [Related]
7. Molecular pathogenesis of pediatric astrocytic tumors.
Nakamura M; Shimada K; Ishida E; Higuchi T; Nakase H; Sakaki T; Konishi N
Neuro Oncol; 2007 Apr; 9(2):113-23. PubMed ID: 17327574
[TBL] [Abstract][Full Text] [Related]
8. Characterisation of molecular alterations in microdissected archival gliomas.
Walker C; Joyce KA; Thompson-Hehir J; Davies MP; Gibbs FE; Halliwell N; Lloyd BH; Machell Y; Roebuck MM; Salisbury J; Sibson DR; Du Plessis D; Broome J; Rossi ML
Acta Neuropathol; 2001 Apr; 101(4):321-33. PubMed ID: 11355303
[TBL] [Abstract][Full Text] [Related]
9. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas.
Tohma Y; Gratas C; Biernat W; Peraud A; Fukuda M; Yonekawa Y; Kleihues P; Ohgaki H
J Neuropathol Exp Neurol; 1998 Jul; 57(7):684-9. PubMed ID: 9690672
[TBL] [Abstract][Full Text] [Related]
10. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors.
Lang FF; Miller DC; Koslow M; Newcomb EW
J Neurosurg; 1994 Sep; 81(3):427-36. PubMed ID: 8057151
[TBL] [Abstract][Full Text] [Related]
11. Correlation of molecular genetic analysis of p53, MDM2, p16, PTEN, and EGFR and survival of patients with anaplastic astrocytoma and glioblastoma.
Ushio Y; Tada K; Shiraishi S; Kamiryo T; Shinojima N; Kochi M; Saya H
Front Biosci; 2003 May; 8():e281-8. PubMed ID: 12700122
[TBL] [Abstract][Full Text] [Related]
12. Mutations of TP53, amplification of EGFR, MDM2 and CDK4, and deletions of CDKN2A in malignant astrocytomas.
Biernat W; Debiec-Rychter M; Liberski PP
Pol J Pathol; 1998; 49(4):267-71. PubMed ID: 10323080
[TBL] [Abstract][Full Text] [Related]
13. Incidence of p14ARF gene deletion in high-grade adult and pediatric astrocytomas.
Newcomb EW; Alonso M; Sung T; Miller DC
Hum Pathol; 2000 Jan; 31(1):115-9. PubMed ID: 10665922
[TBL] [Abstract][Full Text] [Related]
14. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression.
Nozaki M; Tada M; Kobayashi H; Zhang CL; Sawamura Y; Abe H; Ishii N; Van Meir EG
Neuro Oncol; 1999 Apr; 1(2):124-37. PubMed ID: 11550308
[TBL] [Abstract][Full Text] [Related]
15. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities.
Ichimura K; Bolin MB; Goike HM; Schmidt EE; Moshref A; Collins VP
Cancer Res; 2000 Jan; 60(2):417-24. PubMed ID: 10667596
[TBL] [Abstract][Full Text] [Related]
16. Pilocytic astrocytomas do not show most of the genetic changes commonly seen in diffuse astrocytomas.
Cheng Y; Pang JC; Ng HK; Ding M; Zhang SF; Zheng J; Liu DG; Poon WS
Histopathology; 2000 Nov; 37(5):437-44. PubMed ID: 11119125
[TBL] [Abstract][Full Text] [Related]
17. Independent molecular development of metachronous glioblastomas with extended intervening recurrence-free interval.
Martinez R; Schackert HK; von Kannen S; Lichter P; Joos S; Schackert G
Brain Pathol; 2003 Oct; 13(4):598-607. PubMed ID: 14655763
[TBL] [Abstract][Full Text] [Related]
18. Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter.
Fujisawa H; Kurrer M; Reis RM; Yonekawa Y; Kleihues P; Ohgaki H
Am J Pathol; 1999 Aug; 155(2):387-94. PubMed ID: 10433932
[TBL] [Abstract][Full Text] [Related]
19. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T
Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362
[TBL] [Abstract][Full Text] [Related]
20. PTEN, DMBT1, and p16 alterations in diffusely infiltrating astrocytomas.
Fan X; Muñoz J; Sanko SG; Castresana JS
Int J Oncol; 2002 Sep; 21(3):667-74. PubMed ID: 12168116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
